148 related articles for article (PubMed ID: 20706125)
21. [Duloxetin effective in depression and pain: high remission rates obtained].
MMW Fortschr Med; 2006 Jun; 148(23):63. PubMed ID: 16826744
[No Abstract] [Full Text] [Related]
22. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
23. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder.
Liu X; Chen Y; Faries DE
Clinicoecon Outcomes Res; 2011; 3():63-72. PubMed ID: 21935334
[TBL] [Abstract][Full Text] [Related]
24. [Physical recovery is part of remission].
Krankenpfl J; 2004; 42(3-4):110. PubMed ID: 15311907
[No Abstract] [Full Text] [Related]
25. Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?
Wilhelm S; Boess FG; Hegerl U; Mergl R; Linden M; Schacht A; Schneider E
Expert Opin Drug Saf; 2012 Sep; 11(5):699-711. PubMed ID: 22712514
[TBL] [Abstract][Full Text] [Related]
26. Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.
Bushnell GA; Stürmer T; White A; Pate V; Swanson SA; Azrael D; Miller M
J Affect Disord; 2016 May; 196():138-47. PubMed ID: 26921866
[TBL] [Abstract][Full Text] [Related]
27. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies.
Zhao Y; Wu N; Chen S; Boulanger L; Police RL; Fraser K
Curr Med Res Opin; 2010 Sep; 26(9):2147-56. PubMed ID: 20662557
[TBL] [Abstract][Full Text] [Related]
28. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
[TBL] [Abstract][Full Text] [Related]
29. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia.
Sun P; Zhao Y; Zhao Z; Watson P
Curr Med Res Opin; 2011 Sep; 27(9):1793-801. PubMed ID: 21810060
[TBL] [Abstract][Full Text] [Related]
30. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
[TBL] [Abstract][Full Text] [Related]
31. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
[TBL] [Abstract][Full Text] [Related]
32. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
Liu X; Cui Z; Niu L; Faries DE; Ball T; Johnstone B
Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
[TBL] [Abstract][Full Text] [Related]
33. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
34. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
Cookson J; Gilaberte I; Desaiah D; Kajdasz DK
Int Clin Psychopharmacol; 2006 Sep; 21(5):267-73. PubMed ID: 16877897
[TBL] [Abstract][Full Text] [Related]
35. [Duloxetine reduces pain and depression].
Krankenpfl J; 2004; 42(7-10):246-7. PubMed ID: 15675408
[No Abstract] [Full Text] [Related]
36. Duloxetine treatment of social anxiety disorder with comorbid major depression.
Lin CC
J Clin Psychopharmacol; 2008 Oct; 28(5):591-2; author reply 592-3. PubMed ID: 18794669
[No Abstract] [Full Text] [Related]
37. [Change in the point of view].
Krankenpfl J; 2005; 43(1-3):23-4. PubMed ID: 15912818
[No Abstract] [Full Text] [Related]
38. Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder.
Lai CH
J Clin Psychopharmacol; 2010 Feb; 30(1):88-9. PubMed ID: 20075662
[No Abstract] [Full Text] [Related]
39. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
40. Successful duloxetine treatment of a binge eating disorder: a case report.
Bernardi S; Pallanti S
J Psychopharmacol; 2010 Aug; 24(8):1269-72. PubMed ID: 19010975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
